—Significant and sustained reduction in HAE attacks—
—Oral, once-daily prophylactic option
enables HAE patients to reduce burden of
therapy1 —
—ORLADEYO approved for adult and pediatric patients 12 years and older—
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) — BioCryst
Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug
Neueste Kommentare